Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.03 -3.3%	$0.93	$0.64 ▼ $1.58	$41.35M	-0.8	35,215 shs	3,672 shs
GLYC GlycoMimetics	$0.16 -6.6%	$13.48	$14.06 ▼ $63.00	$10.00M	1.62	65,917 shs	1.05 million shs
MRSN Mersana Therapeutics	$0.34 -9.5%	$0.35	$0.26 ▼ $2.83	$42.86M	0.79	2.77 million shs	4.52 million shs
STTK Shattuck Labs	$0.82 +5.3%	$0.98	$0.69 ▼ $4.99	$39.06M	1.63	333,184 shs	1.25 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	+5.13%	+13.47%	+46.60%	-32.12%
GLYC GlycoMimetics	0.00%	0.00%	-99.01%	-99.30%	-99.46%
MRSN Mersana Therapeutics	0.00%	+18.59%	-6.35%	+3.77%	-83.47%
STTK Shattuck Labs	0.00%	-2.34%	-19.26%	-6.81%	-80.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.4528 of 5 stars	3.5	5.0	0.0	2.7	0.8	1.3
GLYC GlycoMimetics	0.9866 of 5 stars	0.0	3.0	4.6	0.6	1.7	0.0
MRSN Mersana Therapeutics	4.1993 of 5 stars	3.5	3.0	4.1	2.7	2.5	0.0
STTK Shattuck Labs	3.7055 of 5 stars	3.4	5.0	0.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$6.25	509.76% Upside
GLYC GlycoMimetics	2.50	Moderate Buy	N/A	N/A
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,412.07% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.50	819.68% Upside

Current Analyst Ratings Breakdown

Latest GLYC, BRNS, MRSN, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/6/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00 ➝ $3.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	2.76	N/A	N/A	$3.23 per share	0.32
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94
MRSN Mersana Therapeutics	$40.50M	1.06	N/A	N/A	($0.08) per share	-4.30
STTK Shattuck Labs	$5.72M	6.83	N/A	N/A	$1.67 per share	0.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.64	N/A	N/A	N/A	N/A	-46.43%	-38.50%	8/6/2025 (Estimated)
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	8/6/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.39	N/A	N/A	N/A	N/A	-79.69%	-69.13%	7/30/2025 (Estimated)

Latest GLYC, BRNS, MRSN, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	STTK Shattuck Labs	-$0.25	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/14/2025	Q1 2025	GLYC GlycoMimetics	-$5.00	-$4.00	+$1.00	-$0.04	N/A	N/A
5/7/2025	Q1 2025	BRNS Barinthus Biotherapeutics	-$0.34	-$0.49	-$0.15	-$0.49	N/A	N/A
5/1/2025	Q1 2025	STTK Shattuck Labs	-$0.29	-$0.27	+$0.02	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	9.18	9.18
GLYC GlycoMimetics	N/A	1.92	1.92
MRSN Mersana Therapeutics	N/A	1.83	1.83
STTK Shattuck Labs	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
GLYC GlycoMimetics	75.19%
MRSN Mersana Therapeutics	93.92%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
GLYC GlycoMimetics	8.70%
MRSN Mersana Therapeutics	13.00%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	37.11 million	N/A
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
STTK Shattuck Labs	100	47.90 million	42.15 million	Optionable

GLYC, BRNS, MRSN, and STTK Headlines

Recent News About These Companies

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | globenewswire.com

Shattuck Labs Full Year 2024 Earnings: Misses Expectations

March 29, 2025 | uk.finance.yahoo.com

Shattuck Labs reports Q4 EPS (37c), consensus (32c)

March 28, 2025 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)

March 28, 2025 | markets.businessinsider.com

Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | finanznachrichten.de

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

March 27, 2025 | globenewswire.com

Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation

March 18, 2025 | msn.com

Shattuck Labs initiated with an Outperform at Leerink

March 17, 2025 | markets.businessinsider.com

Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock

March 11, 2025 | finance.yahoo.com

H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)

February 21, 2025 | markets.businessinsider.com

Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

February 20, 2025 | markets.businessinsider.com

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 20, 2025 | globenewswire.com

Shattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in Berlin

February 13, 2025 | quiverquant.comQ

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

February 13, 2025 | globenewswire.com

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

February 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLYC, BRNS, MRSN, and STTK Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.02 -0.04 (-3.30%)

Closing price 07/11/2025 03:52 PM Eastern

Extended Trading

$1.03 +0.01 (+0.59%)

As of 07/11/2025 07:04 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-6.63%)

Closing price 06/13/2025

Extended Trading

$0.16 0.00 (0.00%)

As of 06/13/2025 07:49 PM Eastern

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Mersana Therapeutics NASDAQ:MRSN

$0.34 -0.04 (-9.50%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$0.36 +0.02 (+4.39%)

As of 05:47 AM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Shattuck Labs NASDAQ:STTK

$0.82 +0.04 (+5.32%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$0.81 0.00 (-0.31%)

As of 04:01 AM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time